# **Complete Summary**

## **TITLE**

Osteoarthritis: percentage of patients with osteoarthritis pain of mild or moderate severity for whom acetaminophen is the first drug used for initial nonnarcotic pharmacologic therapy to aid with problem tasks.

# SOURCE(S)

MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH. Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum2004 Apr 15;51(2):193-202. PubMed

Pencharz JN, MacLean CH. Measuring quality in arthritis care: the Arthritis Foundation's Quality Indicator set for osteoarthritis. Arthritis Rheum2004 Aug 15;51(4):538-48. [108 references] <a href="PubMed">PubMed</a>

## **Measure Domain**

#### **PRIMARY MEASURE DOMAIN**

**Process** 

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the <u>Measure Validity</u> page.

## **SECONDARY MEASURE DOMAIN**

Does not apply to this measure

# **Brief Abstract**

## **DESCRIPTION**

This measure is used to assess the percentage of patients with osteoarthritis pain of mild or moderate severity for whom acetaminophen is the first drug used for initial nonnarcotic pharmacologic therapy.

# **RATIONALE**

Acetaminophen should be the first drug used because it achieves pain relief comparable to a nonsteroidal anti-inflammatory drug (NSAID) (nonselective and selective) and is less toxic.

The American Board of Family Practice (ABFP) advocates acetaminophen as the first-line pharmacologic agent for treating osteoarthritis (OA). The American Pain Society (APS) recommends acetaminophen as the first-line pharmacologic therapy in patients with mild OA.

## PRIMARY CLINICAL COMPONENT

Osteoarthritis; nonnarcotic pharmacologic therapy; acetaminophen

#### **DENOMINATOR DESCRIPTION**

Patients with osteoarthritis pain of mild or moderate severity for whom nonnarcotic pharmacologic therapy is initiated

## **NUMERATOR DESCRIPTION**

Patients for whom acetaminophen is the first drug used, unless there is documented contraindication for use

# **Evidence Supporting the Measure**

## **EVIDENCE SUPPORTING THE CRITERION OF QUALITY**

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence
- A formal consensus procedure involving experts in relevant clinical, methodological, and organizational sciences

# **Evidence Supporting Need for the Measure**

## **NEED FOR THE MEASURE**

Unspecified

# **State of Use of the Measure**

## **STATE OF USE**

Current routine use

## **CURRENT USE**

Internal quality improvement

# **Application of Measure in its Current Use**

# **CARE SETTING**

Ambulatory Care
Physician Group Practices/Clinics

## PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Advanced Practice Nurses Physician Assistants Physicians

## LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

**Individual Clinicians** 

#### **TARGET POPULATION AGE**

Unspecified

## **TARGET POPULATION GENDER**

Either male or female

## STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

# **Characteristics of the Primary Clinical Component**

## INCIDENCE/PREVALENCE

Osteoarthritis (OA) is the most common form of arthritis. It is a degenerative joint disease that affects about 12% of the general population, with prevalence increasing with age. Between 60% and 70% of individuals aged 65 years or older show radiographic changes consistent with OA, and about half of these meet classification criteria for the disease by reporting joint pain or stiffness.

# **EVIDENCE FOR INCIDENCE/PREVALENCE**

Hawker G. Epidemiology of arthritis and osteoporosis. 1st ed. Toronto (ON): Institute for Clinical Evaluative Sciences (ICES); 1998.

Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum1998 May;41(5):778-99. PubMed

# **ASSOCIATION WITH VULNERABLE POPULATIONS**

See "Incidence/Prevalence" field.

## **BURDEN OF ILLNESS**

Pain and disability are the most common consequences of osteoarthritis (OA) joint damage.

## **EVIDENCE FOR BURDEN OF ILLNESS**

Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, Sowers M, McAlindon T, Spector TD, Poole AR, Yanovski SZ, Ateshian G, Sharma L, Buckwalter JA, Brandt KD, Fries JF. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med2000 Oct 17;133(8):635-46. [120 references] PubMed

#### **UTILIZATION**

Unspecified

#### **COSTS**

Unspecified

**Institute of Medicine National Healthcare Quality Report Categories** 

## **IOM CARE NEED**

Living with Illness

## **IOM DOMAIN**

Effectiveness

## **Data Collection for the Measure**

## **CASE FINDING**

Users of care only

## **DESCRIPTION OF CASE FINDING**

Patients with osteoarthritis pain of mild or moderate severity for whom nonnarcotic pharmacologic therapy is initiated

## **DENOMINATOR SAMPLING FRAME**

Patients associated with provider

## **DENOMINATOR INCLUSIONS/EXCLUSIONS**

## **Inclusions**

Patients with osteoarthritis pain of mild or moderate severity for whom nonnarcotic pharmacologic therapy is initiated

#### **Exclusions**

Unspecified

#### RELATIONSHIP OF DENOMINATOR TO NUMERATOR

All cases in the denominator are equally eligible to appear in the numerator

# **DENOMINATOR (INDEX) EVENT**

Clinical Condition Therapeutic Intervention

## **DENOMINATOR TIME WINDOW**

Time window is a single point in time

## **NUMERATOR INCLUSIONS/EXCLUSIONS**

#### **Inclusions**

Patients for whom acetaminophen is the first drug used

## **Exclusions**

Patients with documented contraindication to use of acetaminophen

# MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

## **NUMERATOR TIME WINDOW**

Encounter or point in time

# **DATA SOURCE**

Administrative and medical records data Administrative data and patient survey Medical record Patient survey

## LEVEL OF DETERMINATION OF QUALITY

Individual Case

## **PRE-EXISTING INSTRUMENT USED**

Unspecified

# **Computation of the Measure**

#### **SCORING**

Rate

#### **INTERPRETATION OF SCORE**

Better quality is associated with a higher score

## **ALLOWANCE FOR PATIENT FACTORS**

Unspecified

## STANDARD OF COMPARISON

Internal time comparison

# **Evaluation of Measure Properties**

## **EXTENT OF MEASURE TESTING**

A multidisciplinary expert panel comprised of nationally recognized experts discussed and rated the validity of each of the proposed measures based on the evidence and their expert opinion using a modification of the RAND/UCLA Appropriateness Method.

# **EVIDENCE FOR RELIABILITY/VALIDITY TESTING**

MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH. Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum2004 Apr 15;51(2):193-202. PubMed

Pencharz JN, MacLean CH. Measuring quality in arthritis care: the Arthritis Foundation's Quality Indicator set for osteoarthritis. Arthritis Rheum2004 Aug 15;51(4):538-48. [108 references] <a href="PubMed">PubMed</a>

# **Identifying Information**

## **ORIGINAL TITLE**

Quality indicator 11. Initial pharmacologic therapy.

## **MEASURE COLLECTION**

## The Arthritis Foundation's Quality Indicator Project

## **MEASURE SET NAME**

The Arthritis Foundation's Quality Indicator Set for Osteoarthritis

#### **SUBMITTER**

Arthritis Foundation

## **DEVELOPER**

Arthritis Foundation RAND Health

## **ADAPTATION**

Measure was not adapted from another source.

## **RELEASE DATE**

2004 Aug

#### **MEASURE STATUS**

This is the current release of the measure.

## SOURCE(S)

MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH. Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum2004 Apr 15;51(2):193-202. <a href="PubMed">PubMed</a>

Pencharz JN, MacLean CH. Measuring quality in arthritis care: the Arthritis Foundation's Quality Indicator set for osteoarthritis. Arthritis Rheum2004 Aug 15;51(4):538-48. [108 references] <a href="PubMed">PubMed</a>

#### **MEASURE AVAILABILITY**

The individual measure, "Quality Indicator 11. Initial Pharmacologic Therapy," is published in "Measuring Quality in Arthritis Care: The Arthritis Foundation's Quality Indicator Set for Osteoarthritis."

For more information contact: Arthritis Foundation

P.O. Box 7669

Atlanta, GA 30357-0669

Telephone: 404-872-7100 or 1-800-568-4045

Web site: www.arthritis.org

OR

RAND Health 1776 Main Street P.O. Box 2138 Santa Monica, CA 90407

Santa Monica, CA 90407-2138

Telephone: (310) 393-0411, ext. 7775

Web site: <a href="www.rand.org/health">www.rand.org/health</a> E-mail: <a href="mailto:RAND">RAND</a> Health@rand.org

## **NQMC STATUS**

This NQMC summary was completed by ECRI on August 24, 2006. The information was verified by the measure developer on November 6, 2006.

#### **COPYRIGHT STATEMENT**

No copyright restrictions apply.

#### Disclaimer

## **NQMC DISCLAIMER**

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at

http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

© 2008 National Quality Measures Clearinghouse

Date Modified: 11/3/2008

